LOGIN
Combined Treatment With SGLT2 Inhibitors and Metformin For Type 2 Diabetes Mellitus on Fracture Risk
April 2025
Combined Treatment With SGLT2 Inhibitors and Metformin For Type 2 Diabetes Mellitus on Fracture Risk
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials
Osteoporos Int. 2020 Dec;31(12):2313-2320.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Twenty-five randomized controlled trials including 19,500 patients with type 2 diabetes mellitus were included in this systematic review and meta-analysis comparing SGLT2 inhibitors combined with metformin vs. metformin monotherapy or other comparators. Pooled outcomes of interest included overall fracture risk, fracture location (hip/lumbar spine vs. other), drug-specific risk, follow-up duration...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.